Open AccessA Case Report of Triple-Positive Micropapillary Carcinoma of the Male Breast
Author(s) -
Jamila Shuja,
Iftikhar Ahmad,
Sidra Arshad,
Hina Manzoor,
Shahwali Kakar,
Khushnaseeb Ahmad
Publication year - 2018
Publication title -
breast care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.767
H-Index - 30
eISSN - 1661-3805
pISSN - 1661-3791
DOI - 10.1159/000486665
Subject(s) - medicine , modified radical mastectomy , tamoxifen , malignancy , breast carcinoma , estrogen receptor , oncology , axillary lymph nodes , male breast cancer , cyclophosphamide , breast cancer , progesterone receptor , lymph node , histopathology , mastectomy , chemotherapy , pathology , cancer
Background: Micropapillary carcinoma (MPC), a morphologically distinct subtype of invasive ductal carcinoma, of the male breast is an exceedingly uncommon disease. Case Report: Herein, we report a case of triple-positive MPC of the male breast with axillary lymph node involvement and no recurrence for over 2 years. Specifically, a 60-year-old male patient presented with a hard, elastic, and well-defined painless mass in the right breast. The patient underwent unilateral (right) modified radical mastectomy with axillary clearance. Histopathology revealed MPC grade 3 and metastasis in 16/16 lymph nodes. Hormone receptor analysis demonstrated strong positivity (total score 08) for estrogen/progesterone receptors and overexpression (score 3+) of human epidermal growth factor receptor 2. The patient received adjuvant chemotherapy (6 courses of CAF: cyclophosphamide, doxorubicin, and 5-fluorouracil), radiation, and tamoxifen. The patient has remained disease-free for over 2 years. Conclusion: This study demonstrates that triple-positive MPC of the male breast as a rare malignancy appears to respond promisingly to multimodality treatment.